ArticleAmerican journal of respiratory and critical care medicine2024
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.
Open access · greenAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.The European respiratory journal · 2025Trial
- The Iron Lung: Ferroptosis and Iron Regulation in Aging and Lung Diseases.Physiology (Bethesda, Md.) · 2026Review
- Research progress on the discovery and mechanism of nutritional intervention substances for pulmonary fibrosis: a focus on astragalus and its bioactive components.Open life sciences · 2026Review
- Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025Review
- Emerging Concepts in Therapeutic Interventions for Idiopathic Pulmonary Fibrosis.Seminars in respiratory and critical care medicine · 2025Review
- Proteomic Biomarkers of Survival in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease.American journal of respiratory and critical care medicine · 2025Article
- Deciphering the interplay: circulating cell-free DNA, signaling pathways, and disease progression in idiopathic pulmonary fibrosis.3 Biotech · 2025Review
- Neutrophils as key drivers of pulmonary fibrosis: unveiling mechanisms and therapeutic implications.Frontiers in immunology · 2025Review
- IGF-II regulates lysyl oxidase propeptide and mediates its effects in part via basic helix-loop-helix E40.Matrix biology : journal of the International Society for Matrix Biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 20 institutions in 4 countries.
Sydney B MontesiDivision of Pulmonary and Critical Care Medicine and.
Christian R GomezDivision of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-5323-9507
Michael BeersPulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-2149-3209
Robert BrownProgram in Neurotherapeutics, University of Massachusetts Chan Medical School, Worchester, Massachusetts.
Ishanu ChattopadhyayDeparment of Medicine, University of Chicago, Chicago, Illinois.
Kevin R FlahertyDivision of Pulmonary and Critical Care Medicine.ORCID 0000-0001-7686-0291
Christine Kim GarciaDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-0771-1249
Brigitte GompertsDepartment of Pediatrics, David Geffen School of Medicine.ORCID 0000-0002-1809-723X
Lida P HaririDivision of Pulmonary and Critical Care Medicine and.
Cory M HogaboamWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0002-7929-2119
Naftali KaminskiPulmonary, Critical Care and Sleep Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-5917-4601
Grace Hyun J KimCenter for Computer Vision and Imaging Biomarkers, Department of Radiological Sciences, David Geffen School of Medicine, and.ORCID 0000-0003-1225-3489
Melanie KönigshoffPulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9414-5128
Martin KolbDivision of Respirology, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-3837-1467
Darrell N KottonCenter for Regenerative Medicine, Boston University and Boston Medical Center, Boston, Massachusetts.
Jonathan A KropskiDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-8923-1344
Joseph LaskyPulmonary Fibrosis Foundation, Chicago, Illinois.
Chelsea M MaginDepartment of Bioengineering.ORCID 0000-0002-6988-8584
Toby M MaherKeck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-7192-9149
Mark McCormickPulmonary Fibrosis Foundation, Chicago, Illinois.
Bethany B MooreDepartment of Microbiology and Immunology, and.ORCID 0000-0003-3051-745X
Cheryl Nickerson-NutterThree Lakes Foundation, Northbrook, Illinois.
Justin OldhamDivision of Pulmonary and Critical Care Medicine.ORCID 0000-0003-4957-8869
Anna J PodolanczukDivision of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-9559-1485
Ganesh RaghuDivision of Pulmonary, Sleep and Critical Care Medicine, University of Washington, Seattle, Washington.
Ivan RosasPulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas; and.
Steven M RoweDepartment of Medicine and.
William T SchmidtPulmonary Fibrosis Foundation, Chicago, Illinois.
David SchwartzDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-6743-8443
Jessica E ShorePulmonary Fibrosis Foundation, Chicago, Illinois.
Cathie SpinoDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
J Matthew CraigDivision of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Fernando J MartinezDivision of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-2412-3182
Pulmonary and Critical Care Associates · USPulmonary Fibrosis Foundation · USCornell University · USNational Institutes of Health · USBaylor College of Medicine · USBioengineering Center · RUBoston University · USCedars-Sinai Medical Center · USColumbia University Irving Medical Center · USDr. Scholl Foundation · USImperial College London · GBMassachusetts General Hospital · USMcMaster University · CATulane University · USUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of Chicago · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Massachusetts Chan Medical School · USUniversity of Michigan · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MUAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0MMechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6MRole of Surfactant Proteins in Mediating Noninfectious Inflammatory and FibroproP01HL108793 · NHLBI · DUKE UNIVERSITY · PI NOBLE, PAUL WESLEY · 2012 to 2022
$21.3MSpatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0MAlveolar Epithelial Cell Dysfunction in Pulmonary Fibrosis: Leveraging SFTPC Mutations for Discovery of Molecular and Cellular TargetsR01HL145408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MICHAEL FRANCIS BEERS · 2019 to 2026
$4.6MSurfactant Protein C Mouse Models: A Fit For Purpose Preclinical Platform For Advancing Discovery In And Treatment Of Idiopathic Pulmonary FibrosisU01HL152970 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BEERS, MICHAEL FRANCIS · 2021 to 2024
$3.0MMechanisms of epithelial repair and remodeling in pulmonary fibrosisR01HL153246 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KROPSKI, JONATHAN ANDREW · 2020 to 2024
$2.8MHybrid Hydrogel Biomaterials Comprising Clickable Decellularized Extracellular Matrix for Engineering Dynamic 3D Models of FibrosisR01HL153096 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MAGIN, CHELSEA M · 2020 to 2024
$2.6MVascular Leak and Outcomes in IPFK23HL150331 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MONTESI, SYDNEY · 2020 to 2024
$887kBLRD VA I01 BX002378NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K23 HL150331NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01 HL108793NHLBI NIH HHS R01 HL145372NHLBI NIH HHS R01 HL145408NHLBI NIH HHS R01 HL153096NHLBI NIH HHS R01 HL153246NHLBI NIH HHS U01 HL152970NIDDK NIH HHS P30 DK072482
Abstract
Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8-9, 2022. This workshop was held virtually and was organized into three topic areas:
Indexed as
Biomedical ResearchIdiopathic Pulmonary FibrosisHumansLakesNational Heart, Lung, and Blood Institute (U.S.)Risk FactorsUnited Statesinterstitial lung diseasepulmonary fibrosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.